ARTL Share Price | Artelo Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Artelo Biosciences, Inc. do?

Overview: Artelo Biosciences, Inc. is a biopharmaceutical company focused on licensing, developing, and commercializing treatments that modulate the endocannabinoid system (ECS) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 3.42 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.71 Return on Equity: -1,029.00% Price to Book: 3.42Contact Details: Address: 888 Prospect St Ste 210, LA JOLLA CA: 92037-4261 Tel: 1 760 9431689 Website: http://artelobio.com/

Q: Is Artelo Biosciences, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Artelo Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages show a mildly bullish stance, but the weekly Bollinger Bands and KST are mildly bearish. The Dow Theory indicates a bearish trend on the monthly timeframe. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a 1-month return of -43.03% versus the S&P 500's 2.33%, and a 3-year return of -76.72% compared to the S&P 500's 70.41%. Overall, the current stance is mildly bullish, but the strength is weak, with significant underperformance relative to the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

107.4 k

Shareholding (Dec 2025)

FII

1.49%

Held by 3 FIIs

DII

97.72%

Held by 1 DIIs

Promoter

0.00%

How big is Artelo Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Artelo Biosciences, Inc. has a market capitalization of 3.42 million, with net sales of 0.00 million and a net profit of -9.71 million over the latest four quarters. Shareholder's funds are 2.86 million, and total assets amount to 4.70 million.

View full answer

What does Artelo Biosciences, Inc. do?

22-Jun-2025

Artelo Biosciences, Inc. is a biopharmaceutical company focused on developing treatments that modulate the endocannabinoid system. It has a market cap of $3.42 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Is Artelo Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Artelo Biosciences, Inc. shows a mildly bullish trend despite mixed technical signals and significant underperformance compared to the S&P 500, with a 1-month return of -43.03% and a 3-year return of -76.72%.

View full answer

Compare Artelo Biosciences, Inc. with Similar Stocks

Kiora Pharmaceuticals, Inc.Cyclacel Pharmaceuticals, Inc.Jaguar Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.81

Return on Equity

1,029.00%

Price to Book

-2.94

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

49.76%

6 Months

-54.08%

1 Year

-53.79%

2 Years

-71.05%

3 Years

-80.11%

4 Years

-92.44%

5 Years

-98.55%

Artelo Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-6.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.71

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.17%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-2.94

EV to EBIT

-0.21

EV to EBITDA

-0.21

EV to Capital Employed

-1.48

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.79%)

Foreign Institutions

Held by 3 Foreign Institutions (1.49%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -10.53% vs -22.58% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-3.80",
          "chgp": "26.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-3.80",
          "chgp": "-10.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -31.63% vs -5.38% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.40",
          "val2": "-10.10",
          "chgp": "-12.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.20",
          "val2": "0.30",
          "chgp": "-500.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.90",
          "val2": "-9.80",
          "chgp": "-31.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.80

-3.80

26.32%

Interest

0.10

0.00

Exceptional Items

-1.30

0.00

Consolidate Net Profit

-4.20

-3.80

-10.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -10.53% vs -22.58% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.40

-10.10

-12.87%

Interest

0.30

0.00

Exceptional Items

-1.20

0.30

-500.00%

Consolidate Net Profit

-12.90

-9.80

-31.63%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -31.63% vs -5.38% in Dec 2024

All Annual Results

Company CV

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc.

Pharmaceuticals & Biotechnology

Artelo Biosciences, Inc. is a biopharmaceutical company. The Company is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). It develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The Company is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The Company also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia).

Company Coordinates

Company Details

888 Prospect St Ste 210 , LA JOLLA CA : 92037-4261

Tel: 1 760 9431689

http://artelobio.com/

Registrar Details